search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
BLOOD SCIENCES


during widespread intravascular coagulation. This depletion contributes to hypocoagulability and bleeding risk, with fibrinolysis variably contributing, depending on the stage of the sepsis.21 In suspected DIC, the plasma-to-


serum viscosity (PV:SV) ratio will reflect the consumption of cloting proteins, particularly fibrinogen. A changing PV:SV ratio will indicate evolving coagulopathy and support early recognition of DIC with standard laboratory tests.


Understanding PV:SV Plasma and serum viscosity ratio refers to the relationship between the viscosity of plasma and that of serum from the same patient.22


Category Formula


Measurement conditions Units


Normal Normal


Calculation Final reference


Parameter PV:SV ratio Temperature Viscosity units


Plasma viscosity Serum viscosity PV:SV ratio


Normal PV:SV ratio Normal plasma : serum viscosity ratio. Stage The normal PV is slightly


higher than SV. This reflects the fact that plasma contains fibrinogen and other clotting factors, while serum does not. Therefore, serum viscosity is primarily influenced by the concentration and size of circulating proteins, particularly immunoglobulins and paraproteins, in a patient sample. The PV:SV ratio indicates which protein components are elevated and contribute to abnormal viscosity in a patient sample. Early sepsis is characterised by a


marked increase in plasma viscosity, largely atributable to elevated acute- phase reactants such as fibrinogen and other plasma proteins produced during the systemic inflammatory response to infection.23


In contrast, serum viscosity


may remain within normal limits or show only a modest increase in earlier stages. In more advanced or severe cases, both plasma and serum viscosity become elevated, indicating a wider


of sepsis Early


(hyperinflammatory) Established sepsis


Late / septic shock Plasma Serum ↑ PV:SV


viscosity viscosity ratio ↑↑↑


High ↑↑ ↑↑ ↓ / → ↑ Moderate Rationale


Surge in fibrinogen and acute-phase proteins (plasma viscosity rises more)


Persistent inflammation rises both fibrinogen and immunoglobulins, increasing plasma and serum viscosity


Low-Normal Fibrinogen consumption, possible DIC Illustration of plasma : serum viscosity ratio across stages of sepsis.


rise in circulating proteins, including immunoglobulins, driven by immune activation and dysregulated inflammation. This hyperviscosity state will impair microcirculatory flow and will contribute to organ dysfunction.


Phase-dependent dynamics of the PV:SV ratio The PV:SV ratio exhibits a dynamic, phase-dependent pattern during the progression of sepsis, reflecting


underlying changes in coagulation and inflammatory protein composition. Serial monitoring of the PV:SV ratio


will provide a real-time biomarker indicator of the evolving balance between inflammatory and consumptive processes. When, interpreted with other clinical markers, this ratio has the potential to help identify critical transition points and guide phase-specific therapeutic interventions.


Details/Values/Calculation PV / SV


Measured at 37°C, reported at 25°C


mPa.s or cP, numerically equivalent and interchangeable


1.60 mPa.s (mean PV value) 1.50 mPa.s (mean SV value) 1.60 / 1.50 = 1.06 1.06


June 2026 WWW.PATHOLOGYINPRACTICE.COM 33


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56